Citations

Clear

163 citation(s) found for "Sharp, H L".

Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype
Nasr, Samih H. , Dasari, Surendra , Mills, John R. , Theis, Jason D. , Zimmermann, Michael T. , Vrana, Julie A., Lester, Steven J., McLaughlin, Brooke M. , Gillespie, Robert L. , Highsmith, W. Edward, Kurtin, Paul J. , Fonseca, Rafaël , Lee, John J. , Dispenzieri, Angela , Zimmermann, Michael T

Mayo Clinic

Journal of the American Society of Nephrology | January 3, 2017 | Volume: 28 | Issue: 2 | Pages: 431-438

10.1681/asn.2016090951 | PMID 28049649 Get It

Lysozyme amyloidosis (ALys) is a rare form of hereditary amyloidosis that typically manifests with renal impairment, gastrointestinal (GI) symptoms, and sicca syndrome, whereas cardiac involvement is exceedingly rare and neuropathy has not been reported. Here, we describe a 40-year-old man with renal impairment, cardiac and GI symptoms, and peripheral neuropathy. Renal biopsy specimen analysis revealed amyloidosis with extensive involvement of glomeruli, vessels, and medulla. Amyloid was also detected in the GI tract. Echocardiographic and electrocardiographic findings were consistent with cardiac involvement. Proteomic analysis of Congo red–positive renal and GI amyloid deposits detected abundant lysozyme C protein. DNA sequencing of the lysozyme gene in the patient and his mother detected a heterozygous c.305T>C alteration in exon 3, which causes a leucine to serine substitution at codon 102 (Human Genome Variation Society nomenclature: p.Leu102Ser; legacy designation: L84S). We also detected the mutant peptide in the proband’s renal and GI amyloid deposits. PolyPhen analysis predicted that the mutation damages the encoded protein. Molecular dynamics simulations suggested that the pathogenesis of ALys p.Leu102Ser is mediated by shifting the position of the central β -hairpin coordinated with an antiparallel motion of the C-terminal helix, which may alter the native-state structural ensemble of the molecule, leading to aggregation-prone intermediates.
Chapter 5 Ethical Considerations in the Use of Deep Brain Stimulation
Fiksdal, Alexander , Abulseoud, Osama A. , Sharp, Richard R.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 85-98

10.1201/9781315364759-6 Get It

Can Parents Refuse a Potentially Lifesaving Transplant for Severe Combined Immunodeficiency?
Nickels, Andrew S., Myers, Gary Douglas , Joshi, Avni Y. , Sharp, Richard R. , Lantos, John D. , Johnson, Liza‐Marie , Sharp, Richard R

Mayo Clinic

Pediatrics | June 15, 2016 | Volume: 138 | Issue: 1 | Pages: No page available

10.1542/peds.2016-0892 | PMID 27307145 Get It

If untreated, most children with severe combined immunodeficiency disorder (SCID) will die of complications of infection within the first 2 years of life. Early hematopoietic stem cell transplant (HSCT) is the current standard of care for this disease. Although potentially lifesaving, prognosis of HSCT in SCID is variable depending on a number of host and donor factors. Of the survivors, many develop secondary problems such as chronic graft-versus-host disease or even second malignancies. Posttransplant care is complex and requires great effort from parents to adhere to difficult treatment regimens. In this article, we address the difficult ethical question of what to do if parents choose not to have their child with SCID undergo HSCT but prefer palliative care.
Re: “Telepharmacotherapy for Child and Adolescent Psychiatric Patients” by Cain and Sharp (J Child Adolesc Psychopharm 2016;26:221–228)
McKean, Alastair J. , Voort, Jennifer L. Vande , Bostwick, John , Vande Voort, Jennifer L., Bostwick, J Michael

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | March 30, 2016 | Volume: 26 | Issue: 3 | Pages: 305-305

10.1089/cap.2016.0013 | PMID 27027804 Get It

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, Robert A. , Fuleihan, Ghada El‐Hajj , Bauer, Douglas C. , Camacho, Pauline M., Clines, Gregory A. , Edwards, Beatrice J. , Favus, Murray J., Greenspan, Susan L., McKinney, Ross E. , Pignolo, Robert J. , Sellmeyer, Deborah E. , Clarke, Bart L, Drake, Matthew T. , Clarke, B.L. , Compston, Juliet , Bauer, Douglas C , El-Hajj Fuleihan, Ghada

Mayo Clinic

Journal of Bone and Mineral Research | September 9, 2015 | Volume: 31 | Issue: 1 | Pages: 16-35

10.1002/jbmr.2708 | PMID 26350171 Get It

ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non–Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care
Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Brown, Richard H, Abesada-Terk, Guillermo, Sharp, Philip V, Malafa, Mokenge, Brown, Richard H., Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 17, 2015 | Volume: 11 | Issue: 4 | Pages: 332-337

10.1200/jop.2014.001750 | PMID 25991639 Get It

In this study, academic practice status and treatment year predicted use of adjuvant cisplatin-based chemotherapy.
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation
Rojnueangnit, Kitiwan , Xie, Jing , Gomes, Alicia , Sharp, Angela, Callens, Tom, Chen, Yunjia , Liu, Ying , Abbott, Mary‐Alice , Atkin, Joan, Babovic‐Vuksanovic, Dusica , Barnett, Christopher , Crenshaw, Melissa , Bartholomew, Dennis W., Basel, Lina, Bellus, Gary A. , Ben‐Shachar, Shay , Bialer, Martin G., Bick, David , Blumberg, Bruce , Cortés, Fanny, David, Karen L. , Destrèe, Anne , Rodríguez, Anna Duat , Earl, Dawn , Eswara, Marthanda, Ezquieta, Begoña, Frayling, Ian M. , Frydman, Moshe , Gardner, Kathy, Gripp, Karen W. , Hernández‐Chico, Concepción, Heyrman, Kurt, Ibrahim, Jennifer, Janssens, Sandra , Keena, Beth, Llano‐Rivas, Isabel , Leppig, Kathy, McDonald, Marie , Misra, Vinod K. , Mulbury, Jennifer, Narayanan, Vinodh , Orenstein, Naama, Galvin‐Parton, Patricia , Pedro, Hélio , Pivnick, Enikö K., Powell, Cynthia M. , Randolph, Linda M., Raskin, Salmo , Rubin, Karol, Seashore, Margretta R., Schaaf, Christian P. , Schultz, Meredith, Schorry, Elizabeth K. , Schnur, Rhonda E. , Siqveland, Elizabeth, Tkachuk, Amanda , Tonsgard, James H. , Upadhyaya, Meena , Verma, Ishwar C. , Wallace, Stephanie E , Williams, Charles A. , Zackai, Elaine H. , Zonana, Jonathan, Lázaro, Conxi , Claes, Kathleen , Korf, Bruce R. , Messiaen, Ludwine , Babovic-Vuksanovic, Dusica, Cochran, J. Nicholas , Escobar, Luis Fernando , Hernández-Chico, Concepción, Rosell, Jordi , Scheuerle, Angela E. , Martín, Yolanda , Legius, Eric , Claes, Kathleen B M , Lazaro, Conxi

Mayo Clinic

Human Mutation | July 14, 2015 | Volume: 36 | Issue: 11 | Pages: 1052-1063

10.1002/humu.22832 | PMID 26178382 Get It

Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range
Fuleihan, Ghada El‐Hajj , Bouillon, Roger , Chakhtoura, Marlene , Cooper, Cyrus , Clarke, Bart, Clarke, B.L. , McClung, Michael R. , Singh, Ravinder J. , Cooper, Cyrus , El-Hajj Fuleihan, Ghada

Mayo Clinic

Journal of Bone and Mineral Research | May 8, 2015 | Volume: 30 | Issue: 7 | Pages: 1119-1133

10.1002/jbmr.2536 | PMID 25952470 Get It

ABSTRACT Hypovitaminosis D is prevalent worldwide but proportions vary widely between regions, depending on genetic and lifestyle factors, the threshold to define deficiency, and accuracy of 25-hydroxyvitamin D (25OHD) assays used. Latitude, pollution, concealing clothing, sun exposure, gender, dietary habits, and lack of government regulation account for up to 50% in variations in serum 25OHD levels, whereas genetic polymorphisms in the vitamin D pathway account for less than 5%. Organizations/societies have developed guidelines for recommended desirable 25OHD levels and vitamin D doses to reach them, but their applicability across age groups and populations are still debated. This article and the accompanying online Supporting Information highlight sources of variations in circulating 25OHD levels, uncertainties and knowledge gaps, and analytical problems facing 25OHD assays, while keeping efficacy and safety data as the dominant factors when defining a desirable range for 25OHD levels. We propose a desirable range of 20 to 40 ng/mL (50 to 100 nmol/L), provided precise and accurate assays are used. Although slightly lower levels, 15 to 20 ng/mL, may be sufficient for some infants and adults, higher levels, 40 to 60 ng/mL, may still be safe. This desirable range allows physicians to tailor treatment while taking season, lifestyle, vitamin D intake, and other sources of variation into account. We reserve 25OHD measurements for at-risk patients, defined by disease or lifestyle, and the use of 25OHD assays calibrated against the recommended international standards. Most target groups reach desirable target levels by a daily intake of 400 to 600 IU for children and 800 IU for adults. A total daily allowance of vitamin D of up to 1000 IU in the pediatric age groups, and up to 2000 IU in adults, tailored to an individual patient risk profile, is probably safe over long durations. Additional data are needed to validate the proposed range and vitamin D doses, especially in children, pregnant women, and non-white populations. © 2015 American Society for Bone and Mineral Research.
Building a Central Repository for Research Ethics Consultation Data: A Proposal for a Standard Data Collection Tool
Cho, Mildred K. , Anderson, Nick, Barnard, David , Boyle, Mary B., Capron, Alexander Morgan , Dorfman, Elizabeth, Havard, Kathryn, Reider, Carson, Sadler, John Z. , Sharp, Richard R. , Wilfond, Benjamin S. , McCormick, Jennifer B, Taylor, Holly A. , McCormick, Jennifer Blair , Anderson, Nick, Schwartz, Peter H. , Danis, Marion , Sharp, Richard R

Mayo Clinic

Clinical and Translational Science | March 10, 2015 | Volume: 8 | Issue: 4 | Pages: 376-387

10.1111/cts.12268 | PMID 25758372 Get It

AbstractClinical research ethics consultation services have been established across academic health centers over the past decade. This paper presents the results of collaboration within the CTSA consortium to develop a standard approach to the collection of research ethics consultation information to serve as a foundation for quality improvement, education, and research efforts. This approach includes categorizing and documenting descriptive information about the requestor, research project, the ethical question, the consult process, and describing the basic structure for a consult note. This paper also explores challenges in determining how to share some of this information between collaborating institutions related to concerns about confidentially, data quality, and informatics. While there is much still to be learned to improve the process of clinical research ethics consultation, these tools can advance these efforts, which, in turn, can facilitate the ethical conduct of research.
Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval
Jacobsen, Paul B. , Lee, Ji‐Hyun , Fulp, William J. , Siegel, Erin M. , Shibata, David , Laronga, Christine , Gray, Jhanelle E. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George , Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Malafa, Mokenge P. , Fulp, William, Gray, Jhanelle, Tanvetyanon, Tawee , BROWN, RICHARD, Levine, Richard, Cartwright, Thomas, Abesada-Terk, Guillermo, Malafa, Mokenge, Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | February 26, 2015 | Volume: 11 | Issue: 1 | Pages: e103-e109

10.1200/jop.2014.001525 | PMID 25352389 Get It

Findings suggest that more intensive efforts than audit and feedback will be required to improve the quality of psychosocial care, and that greater recognition of problems with emotional well-being may tax the ability of practices to link patients with appropriate services.